Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$146.26 USD

146.26
4,042,003

-6.94 (-4.53%)

Updated May 29, 2024 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioCryst Begins Study on Galidesivir for Coronavirus Infection

by Zacks Equity Research

BioCryst (BCRX) starts recruitment for a clinical study on its pipeline candidate galidesivir to treat patients with the deadly coronavirus disease.

Pfizer (PFE) Progressing Well With its Coronavirus Program

by Zacks Equity Research

Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.

Neena Mishra headshot

Coronavirus Testing, Vaccines & Treatments: What You Should Know

by Neena Mishra

We discuss latest developments in tests, vaccines and therapies for COVID-19.

Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate

by Zacks Equity Research

Novovax (NVAX) announces plans to initiate clinical study to evaluate its coronavirus vaccine candidate in May, weeks ahead of schedule.

Sanghamitra Saha headshot

4 Good Quality Sector ETFs & Stocks to Buy Right Now

by Sanghamitra Saha

These sectors are extremely well-positioned to survive market shocks. Buy the related ETFs and stocks.

Sweta Jaiswal, FRM headshot

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

by Sweta Jaiswal, FRM

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale

Kinjel Shah headshot

Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy

by Kinjel Shah

Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.

Sanghamitra Saha headshot

These Medical ETFs & Stocks Deserve a Salute on Health Day

by Sanghamitra Saha

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $34.64 in the latest trading session, marking a -0.57% move from the prior day.

Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

by Zacks Equity Research

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.

Sanghamitra Saha headshot

Top Leveraged ETFs of Last Week

by Sanghamitra Saha

These leveraged ETFs won last week despite a broader market bloodbath.

Tirthankar Chakraborty headshot

5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check

by Tirthankar Chakraborty

A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -

Kinjel Shah headshot

Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In

by Kinjel Shah

Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.

Nilanjan Banerjee headshot

Coronavirus Drug & Vaccine: 4 Companies Leading From the Front

by Nilanjan Banerjee

The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.

Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton

Ekta Bagri headshot

Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus

by Ekta Bagri

Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.

Sweta Jaiswal, FRM headshot

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Will Moderna Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Moderna

Tirthankar Chakraborty headshot

Top Stock Trades to Beat Coronavirus Blues in April

by Tirthankar Chakraborty

The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $30.48, moving +1.43% from the previous trading session.

Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine

by Zacks Equity Research

Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.

Top Ranked Momentum Stocks to Buy for March 30th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 30th